These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

566 related articles for article (PubMed ID: 21715434)

  • 1. Contemporary activity of colistin and polymyxin B against a worldwide collection of Gram-negative pathogens: results from the SENTRY Antimicrobial Surveillance Program (2006-09).
    Gales AC; Jones RN; Sader HS
    J Antimicrob Chemother; 2011 Sep; 66(9):2070-4. PubMed ID: 21715434
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Global assessment of the antimicrobial activity of polymyxin B against 54 731 clinical isolates of Gram-negative bacilli: report from the SENTRY antimicrobial surveillance programme (2001-2004).
    Gales AC; Jones RN; Sader HS
    Clin Microbiol Infect; 2006 Apr; 12(4):315-21. PubMed ID: 16524407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial resistance among Gram-negative bacilli isolated from Latin America: results from SENTRY Antimicrobial Surveillance Program (Latin America, 2008-2010).
    Gales AC; Castanheira M; Jones RN; Sader HS
    Diagn Microbiol Infect Dis; 2012 Aug; 73(4):354-60. PubMed ID: 22656912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antimicrobial susceptibility among gram-negative isolates collected from intensive care units in North America, Europe, the Asia-Pacific Rim, Latin America, the Middle East, and Africa between 2004 and 2009 as part of the Tigecycline Evaluation and Surveillance Trial.
    Bertrand X; Dowzicky MJ
    Clin Ther; 2012 Jan; 34(1):124-37. PubMed ID: 22154196
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: review of available interpretative criteria and quality control guidelines.
    Gales AC; Reis AO; Jones RN
    J Clin Microbiol; 2001 Jan; 39(1):183-90. PubMed ID: 11136768
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Potency and spectrum of garenoxacin tested against an international collection of skin and soft tissue infection pathogens: report from the SENTRY antimicrobial surveillance program (1999-2004).
    Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2007 May; 58(1):19-26. PubMed ID: 17383139
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differences in potency and categorical agreement between colistin and polymyxin B when testing 15,377 clinical strains collected worldwide.
    Sader HS; Rhomberg PR; Farrell DJ; Jones RN
    Diagn Microbiol Infect Dis; 2015 Dec; 83(4):379-81. PubMed ID: 26415906
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of susceptibility testing methods for polymyxin.
    Behera B; Mathur P; Das A; Kapil A; Gupta B; Bhoi S; Farooque K; Sharma V; Misra MC
    Int J Infect Dis; 2010 Jul; 14(7):e596-601. PubMed ID: 20045367
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The in-vitro activity of colistin in gram-negative bacteria.
    Tan TY; Ng SY
    Singapore Med J; 2006 Jul; 47(7):621-4. PubMed ID: 16810437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antimicrobial susceptibility of uncommonly isolated non-enteric Gram-negative bacilli.
    Sader HS; Jones RN
    Int J Antimicrob Agents; 2005 Feb; 25(2):95-109. PubMed ID: 15664479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antimicrobial activity of tigecycline tested against nosocomial bacterial pathogens from patients hospitalized in the intensive care unit.
    Sader HS; Jones RN; Dowzicky MJ; Fritsche TR
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):203-8. PubMed ID: 16105565
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of disc diffusion, Etest and broth microdilution for testing susceptibility of carbapenem-resistant P. aeruginosa to polymyxins.
    van der Heijden IM; Levin AS; De Pedri EH; Fung L; Rossi F; Duboc G; Barone AA; Costa SF
    Ann Clin Microbiol Antimicrob; 2007 Aug; 6():8. PubMed ID: 17697363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: report from the SENTRY Antimicrobial Surveillance Program (1998-2004).
    Moet GJ; Jones RN; Biedenbach DJ; Stilwell MG; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Jan; 57(1):7-13. PubMed ID: 17059876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial susceptibility pattern comparisons among intensive care unit and general ward Gram-negative isolates from the Meropenem Yearly Susceptibility Test Information Collection Program (USA).
    Rhomberg PR; Fritsche TR; Sader HS; Jones RN
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):57-62. PubMed ID: 16631338
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colistin susceptibility testing by Etest and disk diffusion methods.
    Galani I; Kontopidou F; Souli M; Rekatsina PD; Koratzanis E; Deliolanis J; Giamarellou H
    Int J Antimicrob Agents; 2008 May; 31(5):434-9. PubMed ID: 18328674
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pitfalls of polymyxin antimicrobial susceptibility testing of Pseudomonas aeruginosa isolated from cystic fibrosis patients.
    Hogardt M; Schmoldt S; Götzfried M; Adler K; Heesemann J
    J Antimicrob Chemother; 2004 Dec; 54(6):1057-61. PubMed ID: 15509615
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Contemporary activity of meropenem and comparator broad-spectrum agents: MYSTIC program report from the United States component (2005).
    Rhomberg PR; Jones RN
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):207-15. PubMed ID: 16949243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro susceptibility pattern of cephalosporin-resistant Gram-negative bacteria.
    Punpanich W; Tantichattanon W; Wongwatcharapaiboon S; Treeratweeraphong V
    J Med Assoc Thai; 2008 Oct; 91 Suppl 3():S21-7. PubMed ID: 19255989
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potency and spectrum trends for cefepime tested against 65746 clinical bacterial isolates collected in North American medical centers: results from the SENTRY Antimicrobial Surveillance Program (1998-2003).
    Sader HS; Fritsche TR; Jones RN
    Diagn Microbiol Infect Dis; 2005 Jul; 52(3):265-73. PubMed ID: 16105569
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC; Hsueh PR
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.